US38406L1035 - ADR
GRACELL BIOTECHNOLOGIES-ADR
NASDAQ:GRCL (2/21/2024, 7:00:01 PM)
After market: 10.25 0 (0%)10.25
+0.01 (+0.05%)
Gracell Biotechnologies, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 314 full-time employees. The company went IPO on 2021-01-08. The firm is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The firm is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.
GRACELL BIOTECHNOLOGIES-ADR
Building 3, 418 Guilin Road, Xuhui District
Shanghai SHANGHAI 215123
P: 862164031522
CEO: William Wei Cao
Employees: 314
Website: https://www.gracellbio.com/
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq:...
中国江苏苏州、上海和美国加利福尼亚州圣迭戈, Feb. 22, 2024 (GLOBE NEWSWIRE) -- 亘喜生物科技集团(纳斯达克股票代码:GRCL;简称“亘喜生物” 或“公司”)...
中国江苏苏州、上海和美国加利福尼亚州圣迭戈, Feb. 20, 2024 (GLOBE NEWSWIRE) -- 亘喜生物科技集团(纳斯达克股票代码:GRCL;简称“亘喜生物” 或“公司”)...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ:...
Here you can normally see the latest stock twits on GRCL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: